Experts Challenge GSK Triple Inhaled COPD Therapy Claims
While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with COPD in NEJM, two clinicians in an accompanying editorial argue that the trial falls short of providing robust evidence for switching strategy.
You may also be interested in...
The German group's pharma chief told Scrip that he does not expect to see any competition in the US in the short term to the soon-to-be off-patent COPD blockbuster, citing the complicated case of GSK's Advair for which there are still no FDA approved generics despite losing exclusivity a while ago.
The drug maker is in the midst of launching several new drugs, including the Shingrix vaccine, the triple COPD therapy Trelegy and the HIV regimen Juluca, hoping new drugs will drive growth as Advair sunsets.
Novartis's recent publication of data from its FLAME study comparing its Ultibro Breezhaler with GSK's Advair/Seretide in reducing COPD exacerbations could lead to a change in guidelines to favor LAMA/LABAs over ICS/LABA products in patients with severe COPD. Boehringer Ingelheim's popular Stiolto Respimat will benefit from FLAME's good will, but GSK's son-of-Advair, Breo, will likely suffer.